Volume 130, Issue 3, Pages 632-638 (March 2006) Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response  Sanaa M. Kamal, Amr E. Fouly, Refaat R. Kamel, Bridgette Hockenjos, Ahmed Al Tawil, Khalifa E. Khalifa, Qi He, Margaret J. Koziel, Khairy M. El Naggar, Jens Rasenack, Nezam H. Afdhal  Gastroenterology  Volume 130, Issue 3, Pages 632-638 (March 2006) DOI: 10.1053/j.gastro.2006.01.034 Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 1 Study design flow chart. Patients were randomized after an 8-week observation period. Patients who did not resolve spontaneously by week 8 were randomized to start treatment immediately at week 8 (group A), week 12 (group B), or week 20 (group C). Patients who resolved spontaneously or withdrew prematurely from treatment were encouraged to return for follow-up. Gastroenterology 2006 130, 632-638DOI: (10.1053/j.gastro.2006.01.034) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 2 SVR rates according to genotype. The x-axis represents the different genotypes. The percent of patients showing SVR is represented on the y-axis. Black bars represent group A patients who started therapy at week 8. White bars represent group B patients who started treatment at week 12. Gray bars represent group C patients who started treatment at week 20. Gastroenterology 2006 130, 632-638DOI: (10.1053/j.gastro.2006.01.034) Copyright © 2006 American Gastroenterological Association Terms and Conditions